Abstract
The recent finding that acetylcholinesterase (AChE) colocalizes with β-amyloid (Aβ), promotes and accelerates Aβ aggregation has renewed an intense interest in developing new multitarget AChE inhibitors as potential diseasemodifying drugs for Alzheimer's therapy. In this review, we first briefly discuss the linkage and complex interplay among the three characteristic hallmarks of Alzheimer's disease (AD): amyloid (Aβ) plaques, neurofibrillary tangles (NFTs), and cholinergic hypofunction. We then review the recent studies on the four marketed cholinesterase inhibitors in term of their multiple activities, potential disease-modifying effects, and the underlying mechanisms of these actions. We finally focus on a new emerging strategy or multitarget AChE inhibitors as effective drugs for AD therapy. We explore some examples of multitarget ChE inhibitors developed in our own and other laboratories, which were purposely designed to address multiple AD etiological targets. These new AChE inhibitors hold great promise for improving cognitive functions in AD patients, slowing down the disease progression, as well as treating behavior problems related to AD.
Keywords: Alzheimer’s disease, β-secretase inhibitors, cholinesterase inhibitors, Disease-modifying drugs, metal chelators, monoamine oxidase inhibitors, multitarget drugs, NMDA receptor antagonists
Current Drug Targets
Title:Novel Chelators Targeting Cell Cycle Arrest, Acetylcholinesterase, and Monoamine Oxidase for Alzheimer's Therapy
Volume: 13 Issue: 8
Author(s): Hailin Zheng, Mati Fridkin and Moussa B.H. Youdim
Affiliation:
Keywords: Alzheimer’s disease, β-secretase inhibitors, cholinesterase inhibitors, Disease-modifying drugs, metal chelators, monoamine oxidase inhibitors, multitarget drugs, NMDA receptor antagonists
Abstract: The recent finding that acetylcholinesterase (AChE) colocalizes with β-amyloid (Aβ), promotes and accelerates Aβ aggregation has renewed an intense interest in developing new multitarget AChE inhibitors as potential diseasemodifying drugs for Alzheimer's therapy. In this review, we first briefly discuss the linkage and complex interplay among the three characteristic hallmarks of Alzheimer's disease (AD): amyloid (Aβ) plaques, neurofibrillary tangles (NFTs), and cholinergic hypofunction. We then review the recent studies on the four marketed cholinesterase inhibitors in term of their multiple activities, potential disease-modifying effects, and the underlying mechanisms of these actions. We finally focus on a new emerging strategy or multitarget AChE inhibitors as effective drugs for AD therapy. We explore some examples of multitarget ChE inhibitors developed in our own and other laboratories, which were purposely designed to address multiple AD etiological targets. These new AChE inhibitors hold great promise for improving cognitive functions in AD patients, slowing down the disease progression, as well as treating behavior problems related to AD.
Export Options
About this article
Cite this article as:
Zheng Hailin, Fridkin Mati and B.H. Youdim Moussa, Novel Chelators Targeting Cell Cycle Arrest, Acetylcholinesterase, and Monoamine Oxidase for Alzheimer's Therapy, Current Drug Targets 2012; 13 (8) . https://dx.doi.org/10.2174/138945012802009026
DOI https://dx.doi.org/10.2174/138945012802009026 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemopreventive Properties of Tolfenamic Acid: A Mechanistic Review
Current Medicinal Chemistry New Cathepsin D Inhibitorswith Hydroxyethylamine Isosteres: Preparation and Characterization
Medicinal Chemistry Mammary Development and Breast Cancer: The Role of Stem Cells
Current Molecular Medicine Glyoxal Induced Transition of Transferrin to Aggregates: Spectroscopic, Microscopic and Molecular Docking Insight
Current Pharmaceutical Biotechnology Advancements within Modern Machine Learning Methodology: Impacts and Prospects in Biomarker Discovery
Current Medicinal Chemistry A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer
Current Drug Metabolism Possible Roles of Microglial Cells for Neurotoxicity in Clinical Neurodegenerative Diseases and Experimental Animal Models
Inflammation & Allergy - Drug Targets (Discontinued) Cyclooxygenase-2 Biology
Current Pharmaceutical Design Prolactin Protects Against the Methamphetamine-Induced Cerebral Vascular Toxicity
Current Neurovascular Research An Overview of the Effect of Weight Loss on Cardiovascular Autonomic Function
Current Diabetes Reviews An Overview of Green Chromatographic Analysis from Pharmaceutical Preparations
Current Analytical Chemistry Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology In Silico Binding Mode Proposed for Flavonoid Ligands of Tau Protein with Interest in Alzheimer's Disease
Current Bioactive Compounds MicroRNAs for the Treatment of Dementia and Alzheimer’s Disease
Current Neurovascular Research Screening of a Chemical Library by HT-G4-FID for Discovery of Selective G-quadruplex Binders
Current Pharmaceutical Design NADPH Oxidases in the Heart
Current Cardiology Reviews Progressive Spatial Memory Impairment, Brain Amyloid Deposition and Changes in Serum Amyloid Levels as a Function of Age in APPswe/PS1dE9 Mice
Current Alzheimer Research Drugs and Medicines in Pregnancy: The Placental Disposition of Opioids
Current Pharmaceutical Biotechnology Levofloxacin-Induced Delirium in a Patient Suffering from Schizoaffective Disorder and Multiple Sclerosis
Current Drug Safety Focusing on New Monoamine Oxidase Inhibitors: Differently Substituted Coumarins As An Interesting Scaffold
Current Topics in Medicinal Chemistry